Helus Pharma Completes US$50-Million Underwritten Offering

On June 25, 2026, Helus Pharma™ (Cboe CA: HELP) (Nasdaq: HELP) completed its underwritten offering of 10,309,280 common shares in the capital of the company at an offering price of US$4.85 per common share, for aggregate gross proceeds of US$50 million.

Helus Pharma™ is the commercial operating name of Cybin Inc., a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. 

The company intends to use the net proceeds from the offering to progress its HLP003 for major depressive disorder, HLP004 for generalized anxiety disorder and HLP005 programs, and for working capital and general corporate purposes.

Aird & Berlis represented Cybin Inc. (d/b/a Helus Pharma™) with a team led by Sherri Altshuler and including Danny Kharazmi, Sean Green, Meredith McCann and Teddy Nikolaou (Capital Markets) and Manjit Singh (Tax).